Get the Stockscreener App
1.92
1.54%
-0.03
Pre-market:
2.65
0.73
+38.02%
Camp 4 Therapeutics Corp stock is traded at $1.92, with a volume of 32,165.
It is down -1.54% in the last 24 hours and down -36.63% over the past month.
Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.
See More
Previous Close:
$1.95
Open:
$1.9991
24h Volume:
32,165
Relative Volume:
0.92
Market Cap:
$37.20M
Revenue:
$264.74M
Net Income/Loss:
$-49.71M
P/E Ratio:
-0.4688
EPS:
-4.0959
Net Cash Flow:
$-43.55M
1W Performance:
+4.07%
1M Performance:
-36.63%
6M Performance:
-79.40%
1Y Performance:
-47.83%
1-Day Range:
$1.8707
$2.00
1-Week Range:
$1.67
$2.00
52-Week Range:
$0.3901
$12.30
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Name
Camp 4 Therapeutics Corp
Sector
Industry
Phone
617-651-8867
Address
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
1.92 | 37.20M | 264.74M | -49.71M | -43.55M | -4.0959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | William Blair | Outperform |
| Aug-16-22 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-22-21 | Downgrade | Craig Hallum | Buy → Hold |
| Sep-24-21 | Reiterated | Craig Hallum | Buy |
| Jun-25-21 | Reiterated | Craig Hallum | Buy |
| Dec-18-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Apr-17-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-05-20 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Jun-28-19 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-01-19 | Reiterated | Craig Hallum | Buy |
| Mar-25-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-25-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-18 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-14-18 | Reiterated | B. Riley FBR | Buy |
| Dec-11-18 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Dec-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| Nov-27-18 | Initiated | Goldman | Neutral |
| Oct-15-18 | Initiated | Jefferies | Hold |
| Sep-28-18 | Reiterated | Craig Hallum | Hold |
| Apr-27-18 | Reiterated | Craig Hallum | Hold |
| Mar-08-18 | Downgrade | Craig Hallum | Buy → Hold |
| Feb-16-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
View All
Camp 4 Therapeutics Corp Stock (CAMP) Latest News
Daily Times Chronicle EventsBoy Scout Troop 42 Pancake Breakfast - Homenewshere.com
CAMP4 Therapeutics to Present Preclinical and Phase 1 Clinical Trial Data at 28th Annual Meeting of the American Society of Gene and Cell Therapy - Nasdaq
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting - The Manila Times
Revolutionary RNA Therapy Shows Promise: CAMP4 Unveils First Human Trial Data at Gene Therapy Conference - Stock Titan
Global School of Chess Announces 100 Full-Scholarship Seats for New Inclusivity & Awareness Camp - Yahoo Finance
Home | Department of Parks and Recreation - City and County of Honolulu (.gov)
Programmable Therapeutics Restore Gene Expression - Mirage News
10 Barrel Brewing Co. and Scout Campers Unveil Camp Coldie: The Ultimate Adventure Beer - The Globe and Mail
Explorer Finds Major Gold Structure in Ontario Camp - streetwisereports.com
Top 3 Health Care Stocks Poised for Big Gains in Q2 - NewsBreak: Local News & Alerts
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2 - Benzinga
CalAmp : Quadro Vehicles S.A. Taps LoJack Italia for Advanced Connected Vehicle Technology and Security - MarketScreener
Manasa Pamboor holds free camp for physiotherapy, speech therapy and counseling - Daijiworld
Free Camp for Physiotherapy, Speech Therapy, and Counselling at Manasa Pamboor - Mangalorean.com
CAMP4 Therapeutics Advances RNA-Based Therapeutics - TipRanks
Promising Developments and Solid Financials Support Buy Rating for CAMP4 Therapeutics - TipRanks
Piper Sandler Keeps Their Buy Rating on CAMP4 Therapeutics Corporation (CAMP) - The Globe and Mail
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update - Yahoo
Gunnison Copper Provides a Construction Update for the Johnson Camp Mine in Southeast Arizona - Yahoo Finance
CAMP4 Appoint Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP To Board - citybiz
Camp4 Therapeutics expands board with two new directors By Investing.com - Investing.com Australia
Camp4 Therapeutics expands board with two new directors - Investing.com
CAMP4 Therapeutics Expands Board with New Director Appointments - TipRanks
Major Leadership Boost: CAMP4 Adds Drug Development Pioneers to Board - StockTitan
Stocks Turn Mixed as Magnificent Seven Stocks Fall - TradingView
Stocks Supported by Strength in Chip Stocks and Lower Bond Yields - TradingView
SMALL CAP IDEA: 'Flu Camp' rapid drug trial firm slashes big pharma costs - This is Money
Orchid Isle Dance Announces Connection Camp in Hawaii: Adventure Travel for the Social Dancer - Yahoo Finance
In Other News This Week: Vento launches €75M Fund II, Curve raises €44M, Perfuze secures €22M and more - Silicon Canals
Stocks Rebound as US Government Shutdown Seems Averted - TradingView
It Might Not Be A Great Idea To Buy Camping World Holdings, Inc. (NYSE:CWH) For Its Next Dividend - Yahoo Finance
KY House passes bill to protect conversion therapy, reverse Beshear’s executive order - Lexington Herald Leader
CAMP4 Therapeutics Corporation (CAMP): Among Penny Stocks with Insider Buying in 2025 - Insider Monkey
12 Penny Stocks with Insider Buying in 2025 - Insider Monkey
(PDF) Combination Therapy in Pulmonary Arterial Hypertension—Targeting the Nitric Oxide and Prostacyclin Pathways - ResearchGate
RFK's plan to make America healthy again? Send people with mental health conditions to farms - Yahoo
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Fox Chase Cancer Center to Hold Fifth Annual Cancer Epigenetics Symposium - Fox Chase Cancer Center
Affordable and Free Summer Camps in Chicago - Mommy Poppins
CAMP4 to Participate in Upcoming Investor Conferences - The Manila Times
3 Key Healthcare Conferences Where CAMP4 Therapeutics Will Share Its regRNA Innovation - StockTitan
Trump to prepare facility at Guantanamo for 30,000 migrants - Reuters
Modest Final Quarter Completes Shaky Biotech IPO Comeback For 2024 - News & Insights
Camp Pendleton, Miramar prep for high winds through their unique terrains - fox5sandiego.com
CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
CAMP4 Therapeutics CEO to Present Corporate Update at J.P. Morgan Healthcare Conference - StockTitan
Here are 71 Mass. life science firms presenting at J.P. Morgan - The Business Journals
CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones - The Manila Times
Strategic Investment Boosts Exploration Plans in Ontario's Gold Camp - Streetwise Reports
Camp4 Therapeutics sees MAD safety and key biomarker data in 2H25 - TipRanks
CAMP4 Therapeutics Advances Urea Cycle Disorder Drug After $82M IPO, Secures BioMarin Partnership - StockTitan
Camp 4 Therapeutics Corp Stock (CAMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
3.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):